# Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control

Study · id `cardio:ct-nct07244003` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07244003](<https://clinicaltrials.gov/study/NCT07244003>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07244003

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 430 participants.

## Technical summary

Registry record NCT07244003. Randomized; no masking; primary purpose treatment. Start 2025-03-29 (actual); primary completion 2027-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 430 participants (planned count; ClinicalTrials.gov record NCT07244003, source copy `cardio:ctgov-nct07244003-2025-11-24`, retrieved 2026-10-26)
- Started: 2025-03-29 (actual) (ClinicalTrials.gov record NCT07244003, source copy `cardio:ctgov-nct07244003-2025-11-24`, retrieved 2026-10-26)
- Primary completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT07244003, source copy `cardio:ctgov-nct07244003-2025-11-24`, retrieved 2026-10-26)
- Completion: 2028-06-30 (anticipated) (ClinicalTrials.gov record NCT07244003, source copy `cardio:ctgov-nct07244003-2025-11-24`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07244003, source copy `cardio:ctgov-nct07244003-2025-11-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07244003-2025-11-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control
- Acronym: MESSAGE
- Condition: T2DM (Type 2 Diabetes Mellitus)
- Intervention (Drug): Metformin
- Intervention (Drug): Triple Therapy of Other Oral Antidiabetic Drugs
- Intervention (Drug): ganagliflozin
- Intervention (Drug): liraglutide
- Lead sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (`cardio:org-hangzhou-zhongmei-huadong-pharmaceutical-co-ltd`)

## Provenance

Content hash: 94ad0c3eefed3a6a9ef6531d35b3367aec30bd600378edabb95b0d860561eece
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
